Webb12 jan. 2024 · In a post-authorization safety study, major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, were observed more frequently with XELJANZ (tofacitinib) (5 mg BID or 10 mg BID) compared to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients who were 50 years of age or older … WebbNHS Bath and North East Somerset, Swindon and Wiltshire ICB Royal United Hospitals Bath NHS Foundation Trust Great Western Hospitals NHS Foundation Trust
Drug Safety Update - GOV.UK
Webb7 juli 2024 · Healthcare professionals prescribing dupilumab should be alert to the risks of ocular reactions. New onset or worsening ocular symptoms require prompt review. … list of all basic java programs
Letters and drug alerts sent to healthcare professionals
Webb16 aug. 2024 · Medicine Recalls and Notifications Post-publication note Letters In July 2024, the following letters were sent or provided to relevant healthcare professionals: … WebbXeljanz (tofacitinib) is subject to additional monitoring. This will allow quick identification of new safety information. Health care professionals should report any adverse events … Webb8 feb. 2024 · In July 2024, the FDA added a boxed warning to tofacitinib advising of the increased risk for pulmonary embolism and death associated with the 10-mg twice-daily dose. The FDA encouraged health care professionals and patients to report any side effects from tofacitinib or other medications through the FDA MedWatch program online … images of g tawn aircraft